Covid Vaccine Covaxin
-
{
- All
- News
- Videos
-
Over 30% Covaxin Takers Suffered Health Issues After A Year, Claims Study
Nearly one-third of the individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow-up study conducted at BHU.
-
No External Pressure To Accelerate Development Of Covaxin: Bharat Biotech
Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.
-
Government Rubbishes Reports On Approval For Covaxin Due To Political Pressure
The Union Health Ministry today termed as "misleading" and "fallacious" media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
Relief As 2.3 Lakh Doses Arrive Before Delhi Vaccine Centres Shut Down
Covid vaccination centres catering to the 18 years-and-above age group in Delhi were expected to shut down today but for the arrival of over 2.3 lakh doses, which included both Covaxin and Covishield.
-
Over 3 Lakh People Vaccinated In A Day For First Time, Total 13.9 Lakh
India's Covid-19 vaccination drive, which began a week ago on January 16, has covered nearly 14 lakh people already, the Union government has said. The mission of administering the two-dose jab has by accelerated to over three lakh people per day, according to the Union Health Ministry's data.
-
Bharat Biotech's COVID-19 Vaccine 'Covaxin' Commences Phase-3 Trial At AIIMS: Report
Phase-three of human clinical trial of the India-made COVID-19 vaccine candidate Covaxin began at AIIMS in Delhi on Thursday with Dr MV Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other volunteers receiving the first dose.
-
Over 30% Covaxin Takers Suffered Health Issues After A Year, Claims Study
Nearly one-third of the individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow-up study conducted at BHU.
-
No External Pressure To Accelerate Development Of Covaxin: Bharat Biotech
Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.
-
Government Rubbishes Reports On Approval For Covaxin Due To Political Pressure
The Union Health Ministry today termed as "misleading" and "fallacious" media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
Relief As 2.3 Lakh Doses Arrive Before Delhi Vaccine Centres Shut Down
Covid vaccination centres catering to the 18 years-and-above age group in Delhi were expected to shut down today but for the arrival of over 2.3 lakh doses, which included both Covaxin and Covishield.
-
Over 3 Lakh People Vaccinated In A Day For First Time, Total 13.9 Lakh
India's Covid-19 vaccination drive, which began a week ago on January 16, has covered nearly 14 lakh people already, the Union government has said. The mission of administering the two-dose jab has by accelerated to over three lakh people per day, according to the Union Health Ministry's data.
-
Bharat Biotech's COVID-19 Vaccine 'Covaxin' Commences Phase-3 Trial At AIIMS: Report
Phase-three of human clinical trial of the India-made COVID-19 vaccine candidate Covaxin began at AIIMS in Delhi on Thursday with Dr MV Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other volunteers receiving the first dose.
